ストックスクリーナーアプリを入手
31.32
3.09%
-1.00
前日終値:
$32.32
開ける：
$32.35
24時間の取引高:
952.66K
Relative Volume:
0.77
時価総額：
$1.87B
収益：
$66.05M
当期純損益:
$-422.60M
株価収益率:
-4.3194
EPS:
-7.251
ネットキャッシュフロー:
$-384.73M
1週間 パフォーマンス:
-1.54%
1か月 パフォーマンス:
-4.95%
6か月 パフォーマンス:
-10.31%
1年 パフォーマンス:
-24.57%
1日の値動き範囲:
$31.16
$32.52
1週間の範囲:
$29.67
$32.84
52週間の値動き範囲:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
31.32 | 1.87B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research
4 High-Risk Stocks Built for Big Returns - The Motley Fool
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - Zacks Investment Research
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Investor Outlook: A 36% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
AGIO Maintained by B of A Securities -- Price Target Raised to $50 - GuruFocus
AGIOS PHARMACEUTICALS, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $50 FROM $46 - Bitget
Agios Pharmaceuticals Stock (AGIO) Opinions on Trading Strategies - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily
Bank of America Corp DE Sells 31,441 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO) - Seeking Alpha
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate - Moomoo
Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes - Sahm
612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC - MarketBeat
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - The Globe and Mail
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Agios Pharmaceuticals (AGIO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Responsive Playbooks and the AGIO Inflection - Stock Traders Daily
FARALLON CAPITAL MANAGEMENT LLC Adds to Agios Pharmaceuticals In - GuruFocus
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds - Sahm
AGIO Maintained by JP Morgan -- Price Target Raised to $34 - GuruFocus
Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co. - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Agios Pharmaceuticals, Inc. (AGIO) And Encourages Investors to Connect - ACCESS Newswire
Agios Pharmaceuticals (AGIO) Chief Medical Officer Sarah Gheuens Sells 30,000 Shares - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 30,000 Shares - MarketBeat
Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade - Stock Titan
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - simplywall.st
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - webull.com
AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares - stocktitan.net
Dimensional Fund Advisors LP Increases Position in Agios Pharmaceuticals, Inc. $AGIO - marketbeat.com
Agios Pharmaceuticals (AGIO) Stock Analysis: High Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Farallon Capital (AGIO) discloses 5.9M-share, 9.9% position in Agios - Stock Titan
Seven Fleet Capital Management LP Has $7.09 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Price to sales forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $39 - Moomoo
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $39 to $55 - Moomoo
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year - Yahoo Finance
AGIO: Q2 2026 delivered $44.7M revenue, strong AQVESME launch, and pipeline progress with ~$1B cash - TradingView
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SARAH GHEUENS | Officer |
Aug 04 '26 |
Proposed Sale |
30.48 |
30,000 |
914,283 |
0 |
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Sale |
37.56 |
4,007 |
150,503 |
84,645 |
| Gheuens Sarah | Officer |
Jul 01 '26 |
Proposed Sale |
37.56 |
4,007 |
150,503 |
0 |
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
8,375 |
0 |
88,652 |
| Ballal Rahul D. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
2,816 |
0 |
15,230 |
| Foster-Cheek Kaye I | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
2,816 |
0 |
10,284 |
| FOUSE JACQUALYN A | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
2,816 |
0 |
154,156 |
| Ho Maykin | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
2,816 |
0 |
19,848 |
| Owen Adams Catherine | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
2,816 |
0 |
10,865 |
| Scadden David | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
2,816 |
0 |
20,419 |
16.71%
大文字化:
|
ボリューム (24 時間):